Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics, Inc. - Common Stock (NQ:AQST)

2.785 -0.045 (-1.59%)
Streaming Delayed Price Updated: 10:03 AM EDT, Apr 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aquestive Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Expands License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film to Additional Global Markets
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for AQST-109 Epinephrine Sublingual Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Announces Publication of Crossover Food Effect Study of Diazepam Nasal Spray in Epilepsia
Peer-reviewed data indicates that food significantly decreases and delays the absorption of diazepam dosed via nasal spray 
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Announces Positive Decision in States’ Suboxone Antitrust Lawsuit on All Claims
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 and Host Conference Call on November 2 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
NASDAQ:AQST Investor Notice: Investigation over Potential Wrongdoing at Aquestive Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 09/29/2022 -- Certain directors of Aquestive Therapeutics, Inc. are under investigation on over potential breaches of fiduciary duties. 
Via SBWire
Aquestive Therapeutics Enters License and Supply Agreement with Pharmanovia for Libervant™ (diazepam) Buccal Film for European and MENA Markets
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
NASDAQ:AQST Investor Notice: Update in Lawsuit Against Aquestive Therapeutics, Inc. Announced
San Diego, CA -- (SBWIRE) -- 08/25/2022 -- The Shareholders Foundation announced an update in the lawsuit that is pending for certain investors in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST). 
Via SBWire
NASDAQ:AQST Shareholder Notice: Investigation over Potential Wrongdoing at Aquestive Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 03/09/2022 -- Certain directors of Aquestive Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shareholder Notice: Update in Lawsuit
San Diego, CA -- (SBWIRE) -- 01/19/2022 -- An update was announced in the lawsuit that is pending for certain investors in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST). 
Via SBWire
SHAREHOLDER ALERT: Robbins LLP Investigates Aquestive Therapeutics, Inc. (AQST) on Behalf of Shareholders
From Robbins LLP
Via Business Wire
NASDAQ:AQST Long Term Investor Notice: Investigation over Possible Wrongdoing at Aquestive Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 05/24/2021 -- Certain directors of Aquestive Therapeutics, Inc. are under investigation over possible breaches of fiduciary duties. 
Via SBWire
Topics Lawsuit
Exposures Financial Legal Product Safety
DEADLINE TODAY: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
AQST Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Aquestive Therapeutics, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 30, 2021
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
FRIDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aquestive Therapeutics, Inc. (AQST)
From The Law Offices of Frank R. Cruz
Via Business Wire
FRIDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.